HRT After 65: A Different Conversation

Educational only. Not medical advice. HRT decisions after 65 require careful individualized assessment. If you are over 65 and considering starting or continuing HRT, discuss with a clinician experienced in menopause management for older women.

The HRT conversation at 65 is fundamentally different from the conversation at 52. The timing hypothesis that makes early-initiated HRT favorable does not extend indefinitely. Risks shift. Benefits may persist for some indications but diminish for others. The clinical guidelines become more cautious - not because HRT suddenly becomes dangerous on your 65th birthday, but because the cumulative risk-benefit balance gradually changes with age.

At the same time, some women over 65 continue to experience vasomotor symptoms (approximately 15 to 20% of women in their 60s still have hot flashes), and genitourinary symptoms are progressive without treatment at any age. The answer is not a blanket “stop at 65.” It is a nuanced, individualized reassessment.

• Continuing established HRT is a clinically different situation from initiating HRT de novo after 65. The evidence is more favorable for continuation
• Starting systemic HRT for the first time after age 65 or more than 10 to 15 years past menopause is generally not recommended due to increased cardiovascular and stroke risk
• For women who started HRT within the timing window and have been on it continuously, annual reassessment of the benefit-risk balance is appropriate - but arbitrary discontinuation at 65 is not evidence-based
• Vaginal estrogen for GSM has no age limit and should be continued (or started) whenever genitourinary symptoms are present, regardless of age
• Bone-protective benefits of HRT are maintained only during use. Stopping requires a transition plan for bone protection
• The lowest effective dose principle becomes more important with age, as risk may be more dose-dependent in older women

Continuing established HRT. A woman who started HRT at 52 and has been on it continuously for 13 years has a different risk profile than a woman starting HRT de novo at 65. The vascular protective effects of early-initiated estrogen are maintained during continuous use. The cardiovascular risk of continuing is lower than the risk of initiating in an estrogen-naive older woman. NAMS supports continuing HRT beyond 65 when symptoms persist and the individual benefit-risk balance remains favorable, with periodic reassessment.

Starting HRT de novo after 65. Initiating systemic HRT for the first time in women well past the timing window (more than 10-15 years post-menopause) is generally not recommended. The cardiovascular risk is unfavorable: estrogen may destabilize existing atherosclerotic plaque. VTE risk increases with age. The exception: vaginal estrogen, which can be initiated at any age for GSM with minimal systemic risk.

Cardiovascular risk. Baseline cardiovascular risk increases with age. The absolute risk increase from HRT becomes more significant as the background risk rises. Annual cardiovascular risk assessment is important.

VTE risk. Baseline VTE risk increases with age, immobility, and comorbidities. Transdermal estrogen becomes even more important than in younger women because it does not increase VTE risk the way oral does.

Breast cancer risk. Duration of combined HRT use increases breast cancer risk. For women on long-term combined therapy, the cumulative exposure adds to baseline risk. This is the factor that most influences decisions about continuing combined therapy in older women. Estrogen-only therapy (for women without a uterus) has a more favorable risk profile and may be continued with less concern.

Cognitive effects. The evidence on HRT and cognitive protection is complex. Early initiation may be protective. Late initiation (after 65 in estrogen-naive women) showed no benefit and possible increased dementia risk in the WHIMS substudy. Continuing established HRT does not appear to carry the same risk.

Bone protection. One of the strongest arguments for continuing HRT past 65 in women at risk for osteoporosis. HRT maintains bone density throughout use. Stopping at 65 causes rapid bone loss (3 to 5% in the first 1 to 2 years). For women with osteoporosis or high fracture risk, transitioning to bisphosphonates or denosumab when stopping HRT is essential.

The lowest effective dose principle is more important with age. Many women on long-term HRT can reduce their dose while maintaining symptom control and bone protection. Low-dose and ultra-low-dose estrogen regimens (e.g., estradiol patch 0.014 to 0.025 mg per day) may provide adequate benefit with lower risk. A dose reduction trial - lowering the dose and monitoring symptoms and bone density - is a reasonable approach for women who want to continue with reduced risk.

GSM is progressive. It does not resolve with age. It worsens. Vaginal estrogen at any age treats vaginal dryness, painful intercourse, urinary urgency, recurrent UTIs. Systemic absorption is minimal. No progestogen required. NAMS and ACOG support its use indefinitely.

For women over 65 who stop systemic HRT, continuing (or starting) vaginal estrogen is almost always appropriate. This should be a standard part of any HRT discontinuation conversation for older women.

Every year after 65 (and ideally every year at any age), the HRT conversation should include: are symptoms still present that justify continued use? Have any new risk factors emerged (new cardiovascular disease, new cancer, new VTE risk)? Is the current dose the lowest effective dose? Would a route change reduce risk (oral to transdermal)? If stopping, what is the bone protection transition plan? Is vaginal estrogen being addressed separately?

• I have been on HRT since my 50s - is it safe to continue at my age?
• Should we try reducing my dose to see if I still need the current amount?
• Should I switch from oral to transdermal to reduce my VTE risk?
• If I stop HRT, what happens to my bone density, and what is the transition plan?
• Should I continue (or start) vaginal estrogen regardless of what we do with systemic HRT?